CS
Candriam SCA Portfolio holdings
AUM
$17.3B
1-Year Return
21.68%
This Quarter Return
+9.06%
1 Year Return
+21.68%
3 Year Return
+102.54%
5 Year Return
+176.54%
10 Year Return
+489.52%
AUM
$14.6B
AUM Growth
+$2.59B
(+22%)
Cap. Flow
+$828M
Cap. Flow
% of AUM
5.67%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
968
New
130
Increased
364
Reduced
334
Closed
74
Top Buys
| 1 |
Microsoft
MSFT
|
$144M |
| 2 |
Royal Bank of Canada
RY
|
$123M |
| 3 |
Agilent Technologies
A
|
$78.5M |
| 4 |
UnitedHealth
UNH
|
$71.8M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$70.8M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$92.6M |
| 2 |
Amgen
AMGN
|
$87.9M |
| 3 |
Allstate
ALL
|
$52.7M |
| 4 |
PayPal
PYPL
|
$47.9M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$47.4M |
Sector Composition
| 1 | Healthcare | 33.43% |
| 2 | Technology | 23.21% |
| 3 | Consumer Discretionary | 9.15% |
| 4 | Financials | 8.64% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
UFS
201
DELISTED
DOMTAR CORPORATION (New)
UFS
| $17.4M | 0.12% |
+315,996
| New | +$17.4M |
|
202
Trex
TREX
$6.94B
| $17.4M | 0.12% |
169,907
+21,235
| +14% | +$2.17M |
|
|
FRTA
203
DELISTED
Forterra, Inc
FRTA
| $17.3M | 0.12% |
+734,897
| New | +$17.3M |
|
|
PFPT
204
DELISTED
Proofpoint, Inc.
PFPT
| $17.2M | 0.12% |
+98,981
| New | +$17.2M |
|
205
ICICI Bank
IBN
$113B
| $17.1M | 0.12% |
1,001,321
+21,880
| +2% | +$374K |
|
206
CEVA Inc
CEVA
$545M
| $17.1M | 0.12% |
360,869
+61,178
| +20% | +$2.89M |
|
207
Masco
MAS
$15.8B
| $17M | 0.12% |
288,854
-352,975
| -55% | -$20.8M |
|
208
IBM
IBM
$231B
| $16.8M | 0.12% |
120,163
-6,186
| -5% | -$867K |
|
209
Ally Financial
ALLY
$12.8B
| $16.6M | 0.11% |
333,287
+138,840
| +71% | +$6.92M |
|
210
Norfolk Southern
NSC
$62.3B
| $16.4M | 0.11% |
61,855
+25,786
| +71% | +$6.84M |
|
211
Zymeworks
ZYME
$1.14B
| $16.4M | 0.11% |
473,124
+111,583
| +31% | +$3.87M |
|
212
Schlumberger
SLB
$53.5B
| $16.4M | 0.11% |
511,775
-21,167
| -4% | -$678K |
|
213
Intellia Therapeutics
NTLA
$1.29B
| $16.4M | 0.11% |
101,127
-81,790
| -45% | -$13.2M |
|
214
MacroGenics
MGNX
$129M
| $16.3M | 0.11% |
608,523
-67,607
| -10% | -$1.82M |
|
215
Weyerhaeuser
WY
$18.9B
| $16.3M | 0.11% |
472,721
+352,021
| +292% | +$12.1M |
|
216
Arrowhead Research
ARWR
$3.99B
| $16.3M | 0.11% |
196,408
+32,450
| +20% | +$2.69M |
|
|
IMGN
217
DELISTED
Immunogen Inc
IMGN
| $16.2M | 0.11% |
+2,461,459
| New | +$16.2M |
|
218
PPG Industries
PPG
$24.7B
| $16M | 0.11% |
94,042
+60,653
| +182% | +$10.3M |
|
219
DuPont de Nemours
DD
$32.5B
| $15.7M | 0.11% |
203,265
+133,661
| +192% | +$10.3M |
|
220
Vail Resorts
MTN
$5.85B
| $15.6M | 0.11% |
49,357
+48,611
| +6,516% | +$15.4M |
|
|
DRNA
221
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $15.6M | 0.11% |
418,245
-990,748
| -70% | -$37M |
|
222
Becton Dickinson
BDX
$55B
| $15.6M | 0.11% |
65,718
+21,597
| +49% | +$5.12M |
|
223
Cogent Biosciences
COGT
$1.82B
| $15.5M | 0.11% |
1,910,720
+1,435,911
| +302% | +$11.6M |
|
224
AstraZeneca
AZN
$253B
| $15.4M | 0.11% |
257,386
+93,802
| +57% | +$5.62M |
|
|
TCRR
225
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $15.3M | 0.11% |
934,551
+540,263
| +137% | +$8.87M |
|